Pathogenesis guided therapeutic management of COVID-19: an immunological perspective
- 28 October 2020
- journal article
- review article
- Published by Taylor & Francis in International Reviews of Immunology
- Vol. 40 (1-2) , 54-71
Abstract
Lack of standardized therapeutic approaches is arguably the significant contributor to the high burden of mortality observed in the ongoing pandemic of the Coronavirus disease, 2019 (COVID-19). Evidence is accumulating on SARS-CoV-2 specific immune cell dysregulation and consequent tissue injury in COVID-19. Currently, no definite drugs or vaccines are available against the disease; however initial results of the ongoing clinical trials have raised some hope. In this article, taking insights from the emerging empirical evidence about host-virus interactions, we deliberate upon plausible pathogenic mechanisms and suitable therapeutic approaches for COVID-19.Keywords
Funding Information
- None (None)
This publication has 93 references indexed in Scilit:
- Dysregulated Type I Interferon and Inflammatory Monocyte-Macrophage Responses Cause Lethal Pneumonia in SARS-CoV-Infected MiceCell Host & Microbe, 2016
- Human Coronavirus NL63 Utilizes Heparan Sulfate Proteoglycans for Attachment to Target CellsJournal of Virology, 2014
- CEACAM1 regulates TIM-3-mediated tolerance and exhaustionNature, 2014
- Inhibition of SARS Pseudovirus Cell Entry by Lactoferrin Binding to Heparan Sulfate ProteoglycansPLOS ONE, 2011
- Complement and viral pathogenesisVirology, 2011
- SnapShot: Pathways of Antiviral Innate ImmunityCell, 2010
- Complement and its role in innate and adaptive immune responsesCell Research, 2009
- Adaptive immune features of natural killer cellsNature, 2009
- Analysis of Serum Cytokines in Patients with Severe Acute Respiratory SyndromeInfection and Immunity, 2004
- Recognition of single-stranded RNA viruses by Toll-like receptor 7Proceedings of the National Academy of Sciences, 2004